There is a growing interest in developing multi-target drugs (Athar et al., 2021) that can address various aspects of AD pathology, including anti-Aβ deposition, tau protein phosphorylation, oxidative stress, and mitochondrial autophagy dysfunction. This evidence concerns the gene MAPT and Alzheimer disease.